KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Payables (2016 - 2025)

Exact Sciences has reported Payables over the past 16 years, most recently at $175.9 million for Q4 2025.

  • Quarterly Payables fell 48.08% to $175.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $175.9 million through Dec 2025, down 48.08% year-over-year, with the annual reading at $175.9 million for FY2025, 48.08% down from the prior year.
  • Payables was $175.9 million for Q4 2025 at Exact Sciences, up from $129.4 million in the prior quarter.
  • Over five years, Payables peaked at $349.6 million in Q2 2021 and troughed at $36.0 million in Q1 2021.
  • The 5-year median for Payables is $85.4 million (2022), against an average of $150.1 million.
  • Year-over-year, Payables surged 981.64% in 2021 and then tumbled 75.92% in 2022.
  • A 5-year view of Payables shows it stood at $67.8 million in 2021, then grew by 10.45% to $74.9 million in 2022, then rose by 5.21% to $78.8 million in 2023, then surged by 329.77% to $338.7 million in 2024, then tumbled by 48.08% to $175.9 million in 2025.
  • Per Business Quant, the three most recent readings for EXAS's Payables are $175.9 million (Q4 2025), $129.4 million (Q3 2025), and $157.3 million (Q2 2025).